Key Takeaways for Thermo Fisher Scientific Stock as of July 2026
- Thirty analysts cover Thermo Fisher Scientific stock: 18 buys, 3 outperforms, 7 holds, 2 no opinions, zero sells. The mean target of $591 sits just 12% above the current $527 price, a notably tight spread for a name this size.
- TIKR’s mid-case model prices Thermo Fisher Scientific stock at $811 by year-end 2030, a 54% total return from today’s level, or 10% annualized over the next 4.5 years.
- Following the July 2 Arcturus Therapeutics collaboration, Thermo Fisher will manufacture ARCT-032 for cystic fibrosis and hold exclusive commercial rights if the drug reaches approval, adding a new pharma services revenue line ahead of Q2 earnings on July 23.
Thermo Fisher Stock Rides Clario Integration to a Faster EBITDA Ramp
Thermo Fisher Scientific (TMO) posted first-quarter 2026 revenue of $11.01 billion, up 6% year over year, with adjusted EPS climbing 6% to $5.44. GAAP EPS jumped 11% to $4.43, a sharper move that reflects the underlying operating improvement building beneath the headline growth rate.
That improvement shows up clearest in EBITDA. Q1 EBITDA reached $2.71 billion, up 6.2% year over year at a 24.6% margin, and the forward path steepens from there: consensus has EBITDA growth accelerating to 10% in Q2, 13% in Q3, and 14% by Q4 2026, with margin expanding to 27%.
Much of that lift traces to the Clario acquisition, closed March 24 for roughly $9 billion. Clario added $30 million of revenue and $0.01 of adjusted EPS in its first week inside the company, and management has targeted $175 million of adjusted operating income from the business by year five.
Chairman and CEO Marc Casper addressed the scale of the resulting guidance raise directly on the Q1 call: “We are raising our guidance for the full year on the top and bottom line, incorporating the positive impact of Clario and the strong first quarter earnings performance.” Full-year revenue guidance moved to $47.3 billion to $48.1 billion, with adjusted EPS guided to $24.64 to $25.12.
That raise came before the company’s May 20 Investor Day, where management set a long-term target of 7% organic revenue growth and low-teens adjusted EPS growth, framing 2026 as the first leg of a multiyear re-acceleration rather than a one-quarter pop.
The pipeline kept building into July. On July 2, Arcturus Therapeutics tapped Thermo Fisher to manufacture ARCT-032, its experimental mRNA cystic fibrosis therapy, with exclusive commercial rights attached if the drug clears Phase 3. Days later, the board declared a $0.47 quarterly dividend, and the company confirmed its Q2 print for July 23.
Wall Street’s Tight Target Range on Thermo Fisher Scientific Stock
Thirty analysts carry a consensus rating on Thermo Fisher Scientific stock that skews heavily bullish, with 18 buys and 3 outperforms against just 7 holds and zero sells. The mean target of $591 implies a 12% gain from the current $527 price, a modest spread given the size of the guidance raise delivered in April. High and low targets span $750 to $490, a range of roughly $260 that leaves plenty of room for the mean to move as Clario’s contribution becomes clearer through the back half of 2026.
Wall Street Expects Thermo Fisher Stock’s EBITDA Growth to Peak Near 14% in Late 2026
Thermo Fisher closed Q1 2026 with EBITDA of $2.71 billion, up 6% year over year at a 24.6% margin, the base from which the rest of the year’s acceleration builds.
Consensus has that growth rate roughly doubling over the next two quarters, to 10% in Q2 and 13% in Q3, with margin climbing toward 27%.
The peak lands in Q4 2026, where EBITDA is expected to reach $3.60 billion, up 14% year over year. Growth then cools to 10% in Q1 2027 and 7% by Q2 2027, a deceleration that raises the question of durability.
Bulls point to the 7% long-term organic growth target set at May’s Investor Day as evidence the margin gains persist beyond the Clario integration window. Bears note the drop back to 7% EBITDA growth by mid-2027 as a signal the current ramp is mostly a one-time integration lift rather than a structural reset in operating leverage.
TIKR Values Thermo Fisher Scientific Stock at $811, Pricing a 54% Return by 2030
TIKR’s mid-case model values Thermo Fisher Scientific stock at $811 by year-end 2030, implying a 54% total return from the current price of $527, or 10% annualized over the next 4.5 years.
That annualized profile sits well above the single-digit near-term upside embedded in the Street’s mean target, pointing to a real gap between TIKR’s longer-horizon model and consensus positioning today.
The model’s path leans on the same dynamics driving the current print: Clario’s margin contribution scaling through 2026 and 2027, and the 7% long-term organic growth target management laid out at Investor Day translating into the low-teens adjusted EPS growth the company has now guided toward twice this year.
Should You Invest in Thermo Fisher Scientific Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Thermo Fisher Scientific Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Thermo Fisher Scientific Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze TMO stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
